Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2011 Apr 28;548:2701-13. doi: 10.1021/jm1015022.
Show Gene links
Show Anatomy links
Developing potent human uric acid transporter 1 (hURAT1) inhibitors.
Wempe MF
,
Jutabha P
,
Quade B
,
Iwen TJ
,
Frick MM
,
Ross IR
,
Rice PJ
,
Anzai N
,
Endou H
.
???displayArticle.abstract???
The kidneys are a vital organ in the human body. They serve several purposes including homeostatic functions such as regulating extracellular fluid volume and maintaining acid-base and electrolyte balance and are essential regarding the excretion of metabolic waste. Furthermore, the kidneys play an important role in uric acid secretion/reabsorption. Abnormalities associated with kidney transporters have been associated with various diseases, such as gout. The current study utilized Xenopus oocytes expressing human uric acid transporter 1 (hURAT1; SLC22A12) as an in vitro method to investigate novel compounds and their ability to inhibit (14)C-uric acid uptake via hURAT1. We have prepared and tested a series of 2-ethyl-benzofuran compounds and probed the hURAT1 in vitro inhibitor structure-activity relationship. As compared to dimethoxy analogues, monophenols formed on the C ring showed the best in vitro inhibitory potential. Compounds with submicromolar (i.e., IC(50) < 1000 nM) inhibitors were prepared by brominating the corresponding phenols to produce compounds with potent uricosuric activity.
???displayArticle.pubmedLink???
21449597
???displayArticle.pmcLink???PMC3124071 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
Anzai,
Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.
2008, Pubmed,
Xenbase
Anzai,
Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.
2008,
Pubmed
,
Xenbase
Anzai,
New insights into renal transport of urate.
2007,
Pubmed
Arias,
Deaths: final data for 2001.
2003,
Pubmed
Becker,
Hyperuricemia and associated diseases.
2006,
Pubmed
Biggers,
Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
2008,
Pubmed
Caulfield,
SLC2A9 is a high-capacity urate transporter in humans.
2008,
Pubmed
,
Xenbase
Enomoto,
Molecular identification of a renal urate anion exchanger that regulates blood urate levels.
2002,
Pubmed
,
Xenbase
Feig,
Uric acid and cardiovascular risk.
2008,
Pubmed
Jutabha,
Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux.
2010,
Pubmed
,
Xenbase
Jutabha,
Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate.
2010,
Pubmed
,
Xenbase
Kutzing,
Altered uric acid levels and disease states.
2008,
Pubmed
Lee,
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
2008,
Pubmed
McDonald,
Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate.
2007,
Pubmed
Mount,
Renal urate transport.
2006,
Pubmed
Neogi,
Clinical practice. Gout.
2011,
Pubmed
Pombrio,
Mercapturic acids (N-acetylcysteine S-conjugates) as endogenous substrates for the renal organic anion transporter-1.
2001,
Pubmed
,
Xenbase
Roch-Ramel,
Renal Transport of Urate in Humans.
1999,
Pubmed
Saag,
Epidemiology, risk factors, and lifestyle modifications for gout.
2006,
Pubmed
Sekine,
Expression cloning and characterization of a novel multispecific organic anion transporter.
1997,
Pubmed
,
Xenbase
Shin,
Interactions of urate transporter URAT1 in human kidney with uricosuric drugs.
2011,
Pubmed
Vitart,
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.
2008,
Pubmed
,
Xenbase
